Enfuvirtide: complete guide

Enfuvirtide is a 36-amino-acid synthetic peptide that blocks HIV-1 from fusing with cells. This guide covers its structure, mechanism, approval, TORO trials and status.

Complete guide6 min read

Key takeaway

FDA approved enfuvirtide as Fuzeon on March 13, 2003. It is a linear peptide of 36 amino acids with a molecular weight of 4,492. In the TORO 1 trial, HIV-1 RNA fell by 1.696 log10 copies per mL with enfuvirtide added, versus 0.764 without it. Drugs@FDA now lists Fuzeon as discontinued.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“FDA approved Fuzeon on March 13, 2003.” (this article)
ClassImmune & inflammation
Body systemsImmune system
Studies cited4 in this article · 4 across 1 article on Enfuvirtide
Related productsBPC-157, TB-500 and thymic peptides

Enfuvirtide is an HIV fusion inhibitor, a 36-amino-acid synthetic peptide that stops the virus from merging with a cell. This guide covers its structure, mechanism, FDA-approved use, the two pivotal TORO trials, label warnings and current status. Sources were checked on November 17, 2026.

Quick answer: Enfuvirtide is a prescription HIV-1 fusion inhibitor. Its label covers HIV-1 infection in treatment-experienced patients whose virus keeps replicating despite therapy, always combined with other antiretrovirals. Local skin reactions were nearly universal in trials. Drugs@FDA lists the Fuzeon product as discontinued.

Vitrapep does not sell enfuvirtide; this page is a reference summary of published research and regulatory information.

What is enfuvirtide?

Enfuvirtide is a fusion-inhibitor peptide. The Fuzeon label describes it as “a linear 36-amino acid synthetic peptide with the N-terminus acetylated and the C-terminus is a carboxamide.” It adds that the peptide “is composed of naturally occurring L-amino acid residues” (Fuzeon label, 2019).

It is a peptide in the plainest sense: one unbranched chain of 36 standard amino acids, made by chemical synthesis. Its two ends are capped: an acetyl group at the start and an amide at the end. Our primer on peptide synthesis explains how chains like this are built.

The label gives the empirical formula as C204H301N51O64 and the molecular weight as 4,492. PubChem lists the same formula and weight (PubChem CID 16130199). Drugs@FDA lists the original approval of Fuzeon (NDA 021481, Roche) on March 13, 2003 (Drugs@FDA).

Table 1

Enfuvirtide: key facts

Fact Detail
Structure type Linear 36-amino-acid synthetic peptide, acetylated N-terminus, C-terminal carboxamide
Class HIV-1 gp41 fusion inhibitor
Molecular formula C204H301N51O64
Molecular weight 4,492
First FDA approval March 13, 2003 (Fuzeon, NDA 021481)
Brand names (US) Fuzeon (listed as discontinued in Drugs@FDA)

How does enfuvirtide work?

HIV enters a cell by fusing its outer envelope with the cell membrane. A viral envelope protein called gp41 drives that step by changing shape.

Enfuvirtide’s design came from gp41 itself. A 1994 lab study described DP-178, a peptide matching residues 643 to 678 of HIV-1 gp41. In cell culture, it “consistently blocked 100% of virus-mediated cell-cell fusion” at very low concentrations (Wild et al., 1994). PubChem lists DP-178 and T-20 as synonyms of enfuvirtide.

Enfuvirtide blocks this fold. The label states that it “binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein.” That binding “prevents the conformational changes required for the fusion of viral and cellular membranes.” The virus stays outside the cell.

The label also reports cell culture (in vitro) data. Enfuvirtide was active against HIV-1 clades A, AE, C, D, F and G, and it “has no activity against HIV-2.”

What is enfuvirtide approved for?

The Fuzeon label indicates it “for the treatment of HIV-1 infection in treatment-experienced patients.” Those patients must show “evidence of HIV-1 replication despite ongoing antiretroviral therapy.” The label also requires use “in combination with other antiretroviral agents.”

So two limits are built in. It is for people already treated for HIV-1 whose virus is still replicating. It is used only as part of a combination, never alone.

What did the key trials show?

The first human proof came in 1998. In 16 adults with HIV-1, short-term treatment with T-20 lowered plasma HIV RNA. The authors said the study “provides proof-of-concept that viral entry can be successfully blocked in vivo” (Kilby et al., 1998).

Approval rested on two randomized phase 3 trials in adults with drug-resistant HIV-1, known as TORO 1 and TORO 2. In both, patients got an optimized background regimen of other HIV drugs. They were randomized 2:1 to add enfuvirtide or to take the background regimen alone. The label notes these patients had prior exposure to a median of 12 antiretrovirals over a median of 7 years.

TORO 1 enrolled 501 patients in North and South America. The primary end point was the change in plasma HIV-1 RNA from baseline to week 24. Viral load fell by 1.696 log10 copies per mL with enfuvirtide and 0.764 with the background regimen alone (P < 0.001). CD4 cell counts rose by 76 versus 32 cells per cubic millimeter (P < 0.001) (Lalezari et al., 2003).

TORO 2 enrolled 512 patients in Europe and Australia. At 24 weeks, viral load fell by 1.429 log10 copies per mL with enfuvirtide and 0.648 without it (P < 0.001). CD4 counts rose by 65.5 versus 38.0 cells per cubic millimeter (P = 0.02) (Lazzarin et al., 2003). Both trials were in humans.

What side effects does the label list?

Fuzeon has no boxed warning. Its highlights state: “Most common adverse reactions are local injection site reactions, diarrhea, nausea, and fatigue.” In TORO 1 and TORO 2 combined, 98% of patients had at least one local reaction. These included pain or discomfort (96%), erythema (91%), induration (90%) and nodules or cysts (80%). About 7% stopped treatment because of these reactions or related difficulties.

Excluding local reactions, the most frequent events were diarrhea (31.7%), nausea (22.8%) and fatigue (20.2%). These were also common in the control arm. Other label warnings cover:

  • systemic hypersensitivity reactions, reported in under 1% of patients;
  • a higher rate of bacterial pneumonia in the phase 3 trials (6.7 versus 0.6 events per 100 patient-years);
  • bleeding risk in people with hemophilia or on anticoagulants;
  • immune reconstitution syndrome; and
  • a theoretical risk of antibodies that cause a false positive HIV ELISA test in people without HIV.

Resistance can develop. Per the label, resistant HIV-1 isolates had amino acid changes at positions 36 to 38 of the gp41 HR1 binding region.

What is enfuvirtide’s regulatory status, and how is it used in research?

Enfuvirtide was a prescription drug. Drugs@FDA lists the Fuzeon product under NDA 021481 as discontinued. A DailyMed search for enfuvirtide returned no current labels on November 17, 2026 (DailyMed). The most recent label we could open on FDA’s site is the August 2019 revision. We did not find an FDA safety communication specific to enfuvirtide.

In research, enfuvirtide’s cell culture work is part of its label record. Its activity was measured in CD4+ cells infected with laboratory and clinical HIV-1 isolates. Those in vitro studies also showed how resistance arises in gp41. For other immune-related peptides, see our thymosin alpha-1 guide.

Frequently asked questions about enfuvirtide

Is enfuvirtide a peptide?

Yes. It is a linear synthetic peptide of 36 L-amino acids, with an acetylated start and an amidated end.

What is Fuzeon?

Fuzeon is the brand name for enfuvirtide. FDA approved Fuzeon on March 13, 2003. Drugs@FDA now lists it as discontinued.

How is enfuvirtide different from other HIV drugs?

It blocks the virus from fusing with the cell membrane, so HIV-1 cannot get in. It binds the HR1 region of the viral protein gp41.

Does enfuvirtide work against HIV-2?

No. The label states that enfuvirtide has no activity against HIV-2 in cell culture.

What was its most common side effect?

Local skin reactions where it was given. In the TORO trials, 98% of patients had at least one.

What to know now

  • Structure: linear 36-amino-acid synthetic peptide; C204H301N51O64; molecular weight 4,492.
  • Mechanism: binds HR1 of HIV-1 gp41 and blocks membrane fusion.
  • Approval: Fuzeon, March 13, 2003, for treatment-experienced HIV-1 infection with ongoing replication.
  • Evidence: TORO 1 and TORO 2 showed larger viral load drops with enfuvirtide added (both P < 0.001).
  • Safety: no boxed warning; 98% had local reactions; pneumonia rate was higher in trials.
  • Status: Drugs@FDA lists Fuzeon as discontinued; no current DailyMed label found.

What we’re watching

Any change to the Fuzeon listing in Drugs@FDA or a new enfuvirtide label on DailyMed. Related guides on synthetic peptide drugs: bivalirudin and teduglutide.

More for immune system

All 24 compounds for immune system

Sources: Genentech 2019, FUZEON (enfuvirtide) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: NDA 021481 (FUZEON) . Retrieved November 17, Drugs@FDA: NDA 021481 (FUZEON); National Center for Biotechnology Information 2026, PubChem compound summary for CID 16130199, enfuvirtide; Lalezari 2003, The New England Journal of Medicine, 348; Lazzarin 2003, The New England Journal of Medicine, 348; Wild 1994, Proceedings of the National Academy of Sciences of the United States of America, 91; Kilby 1998, Nature Medicine, 4; U.S. National Library of Medicine 2026, DailyMed SPL listing: enfuvirtide. All 8 citations

Back to the research library

References

  1. Genentech, Inc. (2019). FUZEON (enfuvirtide) prescribing information (revised 8/2019). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021481s033lbl.pdf
  2. U.S. Food and Drug Administration. Drugs@FDA: NDA 021481 (FUZEON). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021481
  3. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 16130199, enfuvirtide. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/16130199
  4. Lalezari, J. P., et al. (2003). Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. The New England Journal of Medicine, 348(22), 2175–2185. https://doi.org/10.1056/NEJMoa035026
  5. Lazzarin, A., et al. (2003). Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. The New England Journal of Medicine, 348(22), 2186–2195. https://doi.org/10.1056/NEJMoa035211
  6. Wild, C. T., et al. (1994). Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proceedings of the National Academy of Sciences of the United States of America, 91(21), 9770–9774. https://doi.org/10.1073/pnas.91.21.9770
  7. Kilby, J. M., et al. (1998). Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Medicine, 4(11), 1302–1307. https://doi.org/10.1038/3293
  8. U.S. National Library of Medicine. (2026). DailyMed SPL listing: enfuvirtide (no results). Retrieved November 17, 2026, from https://dailymed.nlm.nih.gov/dailymed/services/v2/spls.json?drug_name=enfuvirtide